Oncolytic Virus Therapy Market size is poised to surpass USD 1 Billion by the end of 2035, growing at a CAGR of 27% during the forecast period, i.e., 2023 – 2035. In the year 2022, the industry size of oncolytic virus therapy was USD 22.86 Million. The reason behind the growth is impelled by the increasing prevalence of cancer globally which has led to a rapid increase in clinical trials and approval of new virus therapies for cancer treatment. Clinical trials are being conducted to determine the effectiveness of oncolytic viruses since they are effective in treating specific cancer types.
Further, oncolytic viruses (OVs) are an emerging class of cancer therapies that use modified viruses to attack and destroy tumor cells and are being used to treat cancer, particularly advanced metastatic melanoma. According to the World Health Organization (WHO), cancer is a leading cause of death worldwide, accounting for about 10 million death in 2020.
The growing advancements in viral engineering are believed to fuel the market growth. The viral-vector production has had to quickly advance therefore, numerous technological innovations are being tested by businesses to handle every aspect of viral-vector gene therapy, and as genetic engineering technology has advanced, capabilities of the oncolytic virus have been enhanced for creating new anticancer techniques, and the development of tumor-selective oncolytic virus with effectiveness against a variety of malignancies has been made possible.
Growth Drivers
Challenges
|
Base Year |
2022 |
|
Forecast Year |
2023-2035 |
|
CAGR |
~27% |
|
Base Year Market Size (2022) |
~ USD 22.86 Million |
|
Forecast Year Market Size (2035) |
~ USD 1 Billion |
|
Regional Scope |
|
Therapy Type (HSV-based, Adenovirus-based, Reovirus, Poxviruses, NDV)
The HSV-based oncolytic virus therapy market is estimated to gain a robust revenue share of about 30% in the coming years owing to the large number of clinical trials ongoing related to HSV-based viruses. For instance, HSV has two existing variants: HSV Type 1 (HSV-1) and HSV Type 2 (HSV-2). Among these two existing variants HSV-1 has been widely investigated in cancer oncolytic viral therapy. Approximately, 58% of the U.S. population and around 67% of the global population have evidence of exposure to HSV-1 at the same point during their lifetime. Furthermore, genomic manipulation, cytotoxicity, pathogenicity, and the availability of antiviral drugs have resulted in the growing demand for oncolytic HSV-1 widely as a therapeutic approach to melanoma.
End-User (Hospitals, Specialty Clinics, Cancer Research Institutes)
The hospitals segment in the oncolytic virus therapy market is set to garner a notable share in near future as most of the patients approach these facilities for the treatment. Patients with diseases such as cancer, when receiving an early diagnosis in hospitals, their survival rate and chances for successful treatment increase significantly. Within the hospital premises round the clock healthcare professionals including medical oncologists, and other specialists are available to help patients with cancer in the treatment planning.
Our in-depth analysis of the global market includes the following segments:
|
Therapy Type |
|
|
Virus Type |
|
|
Indication |
|
|
Demography |
|
|
End-User |
|
North American Market Forecast
Oncolytic virus therapy market in North America is predicted to account for the largest share of about 39% by the end of 2035 impelled by the growing clinical activities. This has led to the development of new oncolytic viruses’ modifications to existing viruses in the region for serious diseases including cancer. As a result, the demand for oncolytic virus therapy may increase in the region as new modifications would offer more benefits and more patients become eligible for the treatment.
In terms of the number of clinical trial sites, followed by the United States Canada accounts for more than 3% of all global clinical trials.
European Market Statistics
The Europe oncolytic virus therapy market is estimated to be the second largest, during the forecast timeframe led by the rising approvals of oncolytic virus therapy drugs. This has led to the development of new oncolytic viruses’ modifications to existing viruses in the region for serious diseases including cancer. As a result, the demand for oncolytic virus therapy may increase in the region as new modifications would offer more benefits and more patients become eligible for the treatment.
Author Credits: Radhika Gupta, Shivam Bhutani
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?